Probiotics for Recurring UTIs: Oral and Vaginal Preparations Compared

A probiotic sold for vaginal health may also promise fewer urinary infections. Before considering that promise, identify whether its evidence concerns a capsule swallowed each day or a preparation placed in the vagina. The same category name can conceal different treatments.

Who joined the four-group trial?

The Indian trial included 174 women aged 18 to 45, before menopause, with at least three uncomplicated UTIs in the preceding year and a negative baseline urine culture. They received oral and vaginal placebos, an oral probiotic, a vaginal probiotic, or both probiotics. Treatment lasted four months; follow-up extended to a year.¹

This was a prevention study in a selected population. It cannot establish a treatment for an infection already causing symptoms, or a benefit after menopause.

What were the reported recurrence rates?

Table 3 reports these percentages with at least one symptomatic UTI by four months:²

Assigned group	Reported rate
Both placebos	70.45%
Oral probiotic	61.36%
Vaginal probiotic	40.91%
Both probiotics	31.82%

The vaginal and combined groups differed significantly from placebo on this outcome. The oral-only comparison did not.²

There is a reporting problem: the table’s oral-only and vaginal-only percentages do not match their printed fractions, 27/43 and 18/43. The figures above reproduce the published percentages rather than silently correcting the paper.²

These are rates of people experiencing a recurrence, not the percentage reduction in their number of infections. They also show that some participants had infections despite the assigned preparation. Avoid turning the favorable comparison into a promise of complete protection.

The tested schedule is not a generic supplement instruction

Each oral capsule contained 112.5 billion live bacteria. The vaginal tablet contained one billion colony-forming units of three lactobacilli strains. Participants used two oral capsules daily and one vaginal tablet on eight consecutive days each month, with matching placebos as appropriate. The study did not compare probiotics with preventive antibiotics.¹

An oral capsule is not a vaginal tablet. Do not change a product’s route of use to imitate a study. A bottle with different organisms, amounts or instructions needs evidence for its own preparation.

Bring these particulars to a discussion about a proposed product:

• Full organism and strain names, including the letters or numbers after the species.
• The amount of live organisms per dose and the product’s storage instructions.
• Whether it is intended for oral or vaginal use.
• The finished product studied, how often participants used it and how long they were followed.

If a seller supplies only a paper title, ask for the product details that connect the paper to the bottle.

The guideline has not adopted probiotics as routine prevention

The 2025 AUA/CUA/SUFU³ guideline update says its panel cannot recommend Lactobacillus probiotics for recurring-UTI prevention on the available evidence. It recognizes encouraging vaginal-probiotic findings, but says the specific strains matter and that access to studied strains remains a barrier. It finds insufficient high-quality evidence to recommend a commercially available U.S. probiotic for this purpose.³

That position can coexist with a favorable individual trial. Clinical recommendations also require confidence that a preparation can be identified, obtained and used with dependable results across patients.

The guideline offers other prevention options, including cranberry and methenamine hippurate. The latter is a prescription discussion, with its own suitability considerations. Our comparison of methenamine and daily antibiotic prevention examines that choice.³

Agree on a plan for the next episode

Participants who developed symptomatic infections in the probiotic trial received antibiotics selected according to culture results and the hospital protocol. Probiotic prevention did not remove access to infection treatment.¹

Ask your clinician when to provide a urine sample, how to obtain treatment if symptoms recur and how you will judge any prevention plan. Record the episode date, symptoms, culture result when available and treatment, rather than counting every episode of urgency as another infection.

The guideline also recommends considering other causes when symptoms persist after microbiological cure. Repeated symptoms deserve assessment even when adding another supplement seems easier.³

The NHS⁴ advises medical review for recurring infections, including two infections within six months or three within a year. Suspected UTI with fever or shivering, back pain under the ribs, pregnancy or rapidly worsening symptoms needs urgent care.⁴

Chapter 8, “The Bedroom Chapter,” in Laugh, Sneeze, Jump discusses repeat infections and menopause-related changes, and recording symptom and treatment dates. Those details help explain why a prevention trial in younger women may not answer your own treatment question.